THE ROLE OF ER+-FIBROBLASTS IN DRIVING THE AGGRESSIVE PHENOTYPE OF ENDOMETRIOID ENDOMETRIAL CARCINOMA
DOI:
https://doi.org/10.15407/oncology.2025.04.240Keywords:
endometrial cancer, ER+-fibroblasts, tumor microenvironment, clinicopathological featuresAbstract
Summary. The progression of malignant neoplasms depends not only on the phenotypic characteristics of tumor cells, but also on the composition of their microenvironment, particularly cancer-associated fibroblasts. Aim: to investigate the content of ER+-fibroblasts in endometrioid endometrial carcinoma (EEC) and their association with clinicopathological features of the tumor. Object and methods: surgical specimens from 83 patients with EEC, stages I–II and III according to FIGO (median age 60.4 years), were analyzed. Results: poorly differentiated tumors with deep myometrial invasion and stage III disease were characterized by a higher content of ER+-fibroblasts, reduced expression of ER and PR, and increased Ki-67 levels in tumor cells. Conclusion: high ER+-fibroblast content is associated with a more aggressive course of endometrioid endometrial carcinoma, highlighting their potential role as a prognostic marker and a target for further therapeutic research.
References
CANCER IN UKRAINE 2021 - 2022: Incidence, mortality, prevalence and other relevant statistics. Bulletin of the National Cancer Registry of Ukraine, Vol. 24. Kyiv – 2023. Available at: http://ncru.inf.ua/publications/BULL_24/index_e.htm.
Sung H, Ferlay J, Siegel RL, Laversanne, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71 (3): 209–49. https://doi.org/10.3322/caac.21660.
Dhungel N, Dragoi AM. Exploring the multifaceted role of direct interaction between cancer cells and fibroblasts in cancer progression. Front Mol Biosci 2024: 11: 1379971. https://doi.org/10.3389/fmolb.2024.1379971.
Yang D, Liu J, Qian H, Zhuang Q. Cancer-associated fibroblasts: from basic science to anticancer therapy. Exp Mol Med. 2023; 55 (7): 1322–32. https://doi.org/10.1038/s12276-023-01013-0.
Joshi RS, Kanugula SS, Sudhir S, et al. The role of cancer-associated fibroblasts in tumor progression. Cancers (Basel) 2021; 13 (6): 1399. https://doi.org/10.3390/cancers13061399.
Sarkar M, Nguyen T, Gundre E, et al. Cancer-associated fibroblasts: The chief architect in the tumor microenvironment. Front Cell Dev Biol 2023: 11: 1089068. https://doi.org/10.3389/fcell.2023.1089068.
Jia H, Chen X, Zhang L, et al. Cancer associated fibroblasts in cancer development and therapy. J Hematol Oncol 2025; 18 (1): 36. https://doi.org/10.1186/s13045-025-01688-0.
Yuan J, Yang L, Li Z, Zhang H, et al. The role of the tumor microenvironment in endocrine therapy resistance in hormone receptor-positive breast cancer. Front Endocrinol (Lausanne) 2023: 14: 1261283. https://doi.org/ 10.3389/fendo.2023.1261283.
Reid SE, Pantaleo J, Bolivar P, et al. Cancer-associated fibroblasts rewire the estrogen receptor response in luminal breast cancer, enabling estrogen independence. Oncogene 2024; 43 (15): 1113-26. https://doi.org/10.1038/s41388-024-02973-x.
Mangani S, Piperigkou Z, Koletsis NE, et al. Estrogen receptors and extracellular matrix: the critical interplay in cancer development and progression. FEBS J 2025; 292 (7): 1558–72. https://doi.org/10.1111/febs.17270.
Farcas AM, Nagarajan S, Cosulich S, Carroll JS. Genome-Wide Estrogen Receptor Activity in Breast Cancer. Endocrinology 2021; 162 (2): bqaa224. https://doi.org/ 10.1210/endocr/bqaa224.
Blakely B, Shin S, Jin K. Overview of the therapeutic strategies for ER positive breast cancer. Biochem Pharmacol 2023: 212: 115552. https://doi.org/ 10.1016/j.bcp.2023.115552.
Da J, Lu M, Wang Z. Estrogen receptor alpha (ERα)-associated fibroblasts promote cell growth in prostate cancer. Cell Biochem Biophys 2015; 73 (3): 793–8. https://doi.org/10.1007/s12013-015-0700-y.
Subramaniam KS, Tham ST, Mohamed Z. Cancer-associated fibroblasts promote proliferation of endometrial cancer cells. PLoS One 2013; 8 (7): e68923. https://doi.org/10.1371/journal.pone.0068923.
Yeh CR, Slavin S, Da J, et al. Estrogen receptor α in cancer associated fibroblasts suppresses prostate cancer invasion via reducing CCL5, IL6 and macrophage infiltration in the tumor microenvironment. Mol Cancer 2016: 15: 7. https://doi.org/10.1186/s12943-015-0488-9.
Piergentili R, Marinelli E, De Paola L, et al. Epigenetics of endometrial cancer: The role of chromatin modifications and medicolegal implications. Int J Mol Sci 2025; 26 (15): 7306. https://www.mdpi.com/1422-0067/26/15/7306.
Sahoo SS, Ramanand SG, Cuevas IC, et al. A distinct mechanism of epigenetic reprogramming silences PAX2 and initiates endometrial carcinogenesis. JCI Insight 2025; 10 (5): e140989. https://pubmed.ncbi.nlm.nih.gov/32858102.
Gregoricchio S, Kojic A, Hoogstraat M, et al. Endometrial tumorigenesis involves epigenetic plasticity demarcating non-coding somatic mutations and 3D-genome alterations. Genome Biol 2025; 26 (1): 124. doi: 10.1186/s13059-025-03596-5.
Song Y, Zhang K, Zhang J, et al. Epigenetic regulation of nuclear receptors: Implications for endocrine-related diseases and therapeutic strategies. Molecular and Cellular Endocrinology. Genes Dis 2024; 12 (4): 101481. doi: 10.1016/j.gendis.2024.101481.
Li M, Xia Z, Wang R, Xi M, Hou M. Unveiling DNA methylation: early diagnosis, risk assessment, and therapy for endometrial cancer. Frontiers in Oncology. Front Oncol 2025; 14: 1455255. doi: 10.3389/fonc.2024.1455255.
Reid SE, Pantaleo J, Bolivar P, et al. Cancer-associated fibroblasts rewire the estrogen receptor response in luminal breast cancer, enabling estrogen independence. Oncogene 2024; 43 (7): 1113–26. https://doi.org/10.1038/s41388-024-02973-x.
Li Z, Wei H, Li S, Wu P, Mao X. The role of progesterone receptors in breast cancer. Drug Des Devel Ther 2022; 16: 305–14. https://doi.org/10.2147/DDDT.S336643.
Przewoźny S, Rogaliński J, de Mezer M, et al. Estrogen receptor (ER) and progesterone receptor (PgR) expression in endometrial cancer–an immunohistochemical assessment. Diagnostics 2024; 14 (3): 322. https://doi.org/10.3390/diagnostics14030322.
Felix AS, Stone RA, Chivukula M, et al. Survival outcomes in endometrial cancer patients are associated with CXCL12 and estrogen receptor expression. Int J Cancer 2012; 131 (2): E114–21. https://doi.org/10.1002/ijc.27317.25.
Buchynska LG, Movchan OM, Iurchenko NP. Expression of chemokine receptor CXCR4 in tumor cells and content of CXCL12+-fibroblasts in endometrioid carcinoma of endometrium. Exp Oncol 2021; 43 (2): 135–41. https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-2.16240.
